U.S. markets close in 24 minutes

Co-Diagnostics, Inc. (CODX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.1350-0.1750 (-4.06%)
As of 03:36PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.3100
Bid4.1200 x 1300
Ask4.1300 x 1100
Day's Range4.0700 - 4.2800
52 Week Range3.6600 - 11.8200
Avg. Volume632,740
Market Cap139.684M
Beta (5Y Monthly)-1.00
PE Ratio (TTM)4.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
145% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CODX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Co-Diagnostics, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
  • Motley Fool

    Why Co-Diagnostics Stock Slipped Today

    An analyst price target cut was the impetus behind Co-Diagnostics' (NASDAQ: CODX) share price drop on Monday. The biotech's stock lost nearly 4% of its value that day; what didn't help was that the cut was preceded by a recommendation downgrade from a different prognosticator. Co-Diagnostics is now worth $9 per share, in the estimation of H.C. Wainwright's Raghuram Selvaraju.

  • Benzinga

    Co-Diagnostics Looks To Expand Monkeypox Testing Amid Falling COVID-19 Test Revenues

    Co-Diagnostics Inc (NASDAQ: CODX) posted Q2 revenue of $5 million, down from $27.4 million a year ago, way below the consensus of $20.5 million, primarily due to lower demand for the Logix Smart COVID-19 Test. The company posted an operating loss of $(4.1) million compared to an operating income of $11.8 million a year ago due to lower sales volumes and continued investments in R&D. Co-Diagnostics recorded an EPS loss of $(0.08), a shift from an EPS income of $0.33, missing the consensus of $0.1

  • Motley Fool

    Why Shares of Co-Diagnostics Stock Fell 10% on Tuesday

    What happened Co-Diagnostics (NASDAQ: CODX), a maker of molecular diagnostics tests, fell 10% on Tuesday. The stock closed at $7.01 a share on Monday, then opened at $6.95 on Wednesday before dropping to a low of $6.